9 terminated. 9 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Terminated 9 |
| Phase 1 | 1 | Terminated 1 |
Follow pasireotide: new trials by email Literature Review of pasireotide trials Research Report on pasireotide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis Pasireotide 0.9 MG/ML, Saline water - Peritoneal Carcinomatosis | Phase 2 | Terminated | Gustave Roussy, Cancer Campus, Grand Paris | 6 | 2020-09-03 | 2024-02-08 |
| Safety and Efficacy Study of SOM230 s.c. in Cluster Headache SOM230, Placebo - Cluster Headache - Episodic and Chronic | Phase 2 | Terminated | Novartis Pharmaceuticals | 28 | 2016-10-31 | 2021-01-05 |
| Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease Pasireotide with or without cabergoline - Cushings Disease | Phase 2 | Terminated | Novartis Pharmaceuticals | 68 | 2014-03-06 | 2020-09-18 |
| Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor SOM 230 / Pasireotide - Ductal Carcinoma in Situ | Phase 1 / Phase 2 | Terminated | NYU Langone Health | 9 | 2011-06-01 | 2017-12-27 |
| Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer Pasireotide, Everolimus, Laboratory biomarker analysis - Castrate Resistant Prostate Cancer, Chemotherapy Naive Prostate Cancer | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 6 | 2011-06-01 | 2025-04-30 |
| Pasireotide Therapy in Patients With Nelson's Syndrome Pasireotide - Nelson Syndrome | Phase 2 | Terminated | Sheffield Teaching Hospitals NHS Foundation Trust | 8 | 2011-03-01 | 2016-11-02 |
| Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin pasireotide LAR - Pancreatic Neoplasm, Pituitary Neoplasm | Phase 2 | Terminated | Novartis Pharmaceuticals | 118 | 2009-09-01 | 2016-07-26 |
| Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas pasireotide LAR - Gonadotroph Adenomas | Phase 2 | Terminated | University of Pennsylvania | 2 | 2009-06-01 | 2017-11-28 |
| Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma SOM230B - Cancer | Phase 2 | Terminated | University of Utah | 2 | 2008-11-01 | 2014-06-11 |
Pituitary Neoplasms (3) · Nelson Syndrome (2) · ACTH Syndrome, Ectopic (1) · Adrenocortical Hyperfunction (1) · Bronchiolitis Obliterans Syndrome (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Cluster Headache (1) · Meningioma (1) · Neoplasms (1) · Neuroectodermal Tumors, Primitive (1) · Pancreatic Neoplasms (1) · Peritoneal Neoplasms (1) · Pituitary ACTH Hypersecretion (1) · Prostatic Neoplasms (1)
Novartis Pharmaceuticals (3) · Gustave Roussy, Cancer Campus, Grand Paris (1) · NYU Langone Health (1) · Sheffield Teaching Hospitals NHS Foundation Trust (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · University of Pennsylvania (1) · University of Utah (1)
United States (7) · France (3) · Germany (3) · Argentina (2) · Brazil (2) · Italy (2) · Mexico (2) · Spain (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Canada (1) · Colombia (1) · Greece (1) · Hungary (1)
David L Kleinberg, MD (1) · Jianqing Lin, MD (1) · John Newell-Price (1) · Peter J. Snyder, MD (1) · Randy Jensen, MD (1)
2008 (1), 2009 (1), 2019 (1)